Regeneron faces securities lawsuit after melanoma trial failure wipes out $11 billion in market value
AI Summary- Hagens Berman filed a securities class action lawsuit against Regeneron Pharmaceuticals.
- $11 billion in market capitalization was erased after the melanoma trial failure became public.
- Investors covered by the class period bought Regeneron shares from Aug. 1, 2025, through May 15, 2026.